Methods and Compositions for Inhibiting PMP22 Expression

The EPO published patent application EP3426349A1 for Ionis Pharmaceuticals covering compositions and methods for inhibiting PMP22 expression. The patent includes claims directed to antisense oligonucleotides targeting PMP22 mRNA, pharmaceutical compositions containing such compounds, and methods of treating conditions associated with PMP22 overexpression including peripheral neuropathies.

For pharmaceutical companies and biotech firms developing antisense therapeutics, this patent establishes intellectual property protection for PMP22-targeted approaches in Europe. Competitors pursuing similar antisense-based methods for treating conditions like Charcot-Marie-Tooth disease will need to consider freedom-to-operate implications. The patent's broad designation across all EU member states creates a consolidated territorial scope.